In contrast to the effects of BCL-XL and BCL-2 overexpression, FLIPL although functional, did not enhance MYC-driven tumorigenesis, neither with respect to the kinetics nor the relative proportion of myeloid leukemia versus T cell lymphoma compared with MYC alone. The gene discussed is MYC; the disease is T-cell non-Hodgkin lymphoma.